Protalix BioTherapeutics, Inc. (PLX)Healthcare | Biotechnology | Hackensack, United States | NYSE American
2.32 USD
+0.02
(0.870%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.34 +0.02 (0.862%) ⇧ (April 17, 2026, 7:55 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:34 p.m. EDT
Despite the recent 2.0 strike put wall acting as a hard floor, the slide is structural, not a temporary shock; fundamental deterioration (significant revenue drop, negative operating cash flow) combined with a negative model prediction suggests the long-term bullish thesis is currently on life support. The stock has failed to capitalize on the put-heavy short-term positioning, and a 3.62M share stake increase by a promoter appears insufficient to reverse the bleeding fundamentals or the -0.46% predicted directional drift. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.188534 |
| AutoETS | 0.210650 |
| MSTL | 0.210904 |
| AutoTheta | 0.253336 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 53% |
| H-stat | 3.11 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.087 |
| Excess Kurtosis | -1.38 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 17.253 |
| Revenue per Share | 0.672 |
| Market Cap | 186,926,192 |
| Forward P/E | 3.74 |
| Beta | -0.09 |
| Profit Margins | -12.52% |
| Website | https://www.protalix.com |
As of April 18, 2026, 10:34 p.m. EDT: Options flow signals a distinct divergence between short-term hedging and long-term bullish positioning. Near-term expirations (April/May) show heavy Put Open Interest (OI) at the 2.0 strike, creating a 'floor' support zone, alongside a lack of Call OI. Conversely, longer-dated leases (August/November) see significant Call OI at the 5.0 and 7.5 strikes, with minimal Put OI beyond the 2.5 level. Implied Volatility is elevated (~2.5x) for near-term 2.0 strikes but compressed for further out dates, suggesting traders anticipate a choppy recovery or consolidation above 2.0 but view the upside potential to 5.0 as a non-event in the near term, stymied by current fundamentals.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.09019607 |
| Address1 | 2 University Plaza |
| Address2 | Suite 100 |
| All Time High | 912.5 |
| All Time Low | 0.7 |
| Ask | 2.36 |
| Ask Size | 1,900 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 644,250 |
| Average Daily Volume3 Month | 1,235,751 |
| Average Volume | 1,235,751 |
| Average Volume10Days | 644,250 |
| Beta | -0.091 |
| Bid | 2.3 |
| Bid Size | 2,300 |
| Board Risk | 7 |
| Book Value | 0.6 |
| City | Hackensack |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.32 |
| Current Ratio | 2.514 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.34 |
| Day Low | 2.295 |
| Debt To Equity | 17.253 |
| Display Name | Protalix BioTherapeutics |
| Dividend Date | 1,576,800,000 |
| Earnings Call Timestamp End | 1,773,835,200 |
| Earnings Call Timestamp Start | 1,773,835,200 |
| Earnings Timestamp | 1,773,837,000 |
| Earnings Timestamp End | 1,778,243,400 |
| Earnings Timestamp Start | 1,778,243,400 |
| Ebitda | -4,035,000 |
| Ebitda Margins | -0.0765 |
| Enterprise To Ebitda | -40.886 |
| Enterprise To Revenue | 3.128 |
| Enterprise Value | 164,974,208 |
| Eps Forward | 0.62 |
| Eps Trailing Twelve Months | -0.08 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.5998 |
| Fifty Day Average Change | -0.27980018 |
| Fifty Day Average Change Percent | -0.107623726 |
| Fifty Two Week Change Percent | -9.019608 |
| Fifty Two Week High | 3.19 |
| Fifty Two Week High Change | -0.8700001 |
| Fifty Two Week High Change Percent | -0.2727273 |
| Fifty Two Week Low | 1.32 |
| Fifty Two Week Low Change | 0.9999999 |
| Fifty Two Week Low Change Percent | 0.75757563 |
| Fifty Two Week Range | 1.32 - 3.19 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 895,239,000,000 |
| Float Shares | 72,076,168 |
| Forward Eps | 0.62 |
| Forward P E | 3.7419353 |
| Free Cashflow | -12,196,875 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 226 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.1301 |
| Gross Profits | 6,862,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.10135 |
| Held Percent Institutions | 0.23813 |
| Implied Shares Outstanding | 80,571,642 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,576,800,000 |
| Last Split Factor | 1:10 |
| Long Business Summary | Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey. |
| Long Name | Protalix BioTherapeutics, Inc. |
| Market | us_market |
| Market Cap | 186,926,192 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_941520 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -6,604,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 186,926,209 |
| Number Of Analyst Opinions | 2 |
| Open | 2.35 |
| Operating Cashflow | -11,993,000 |
| Operating Margins | -0.51063 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 201 696 9345 |
| Post Market Change | 0.01999998 |
| Post Market Change Percent | 0.8620682 |
| Post Market Price | 2.34 |
| Post Market Time | 1,776,470,107 |
| Previous Close | 2.3 |
| Price Hint | 4 |
| Price To Book | 3.8666663 |
| Price To Sales Trailing12 Months | 3.5440276 |
| Profit Margins | -0.12521 |
| Quick Ratio | 1.499 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.02 |
| Regular Market Change Percent | 0.869564 |
| Regular Market Day High | 2.34 |
| Regular Market Day Low | 2.295 |
| Regular Market Day Range | 2.295 - 2.34 |
| Regular Market Open | 2.35 |
| Regular Market Previous Close | 2.3 |
| Regular Market Price | 2.32 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 536,469 |
| Return On Assets | -0.04414 |
| Return On Equity | -0.14444 |
| Revenue Growth | -0.499 |
| Revenue Per Share | 0.672 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 80,571,642 |
| Shares Percent Shares Out | 0.0584 |
| Shares Short | 4,702,042 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 4,174,736 |
| Short Name | Protalix BioTherapeutics, Inc. |
| Short Percent Of Float | 0.060900003 |
| Short Ratio | 4.55 |
| Source Interval | 15 |
| State | NJ |
| Symbol | PLX |
| Target High Price | 12.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 11.0 |
| Target Median Price | 11.0 |
| Total Cash | 30,273,000 |
| Total Cash Per Share | 0.376 |
| Total Debt | 8,321,000 |
| Total Revenue | 52,744,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.08 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.06095 |
| Two Hundred Day Average Change | 0.2590499 |
| Two Hundred Day Average Change Percent | 0.12569441 |
| Type Disp | Equity |
| Volume | 536,469 |
| Website | https://www.protalix.com |
| Zip | 7,601 |